A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study is a trial of Dexanabinol in patients with advanced solid tumours. The purposes of
this protocol are to study different doses of the study drug to determine the maximum safe
dose and to further understand the safety of the study drug; to understand what the body does
to the study drug; to understand what the study drug does to the body and to measure any
reduction in size of patients' cancer tumour(s).
Dexanabinol is a synthetic cannabinoid derivative with reduced psychotropic potential which
was initially investigated as a neuroprotective agent. Because of its method of action
however it is thought that it may have the effect of destroying cancer cells by reducing the
level of control on networks that prevent cancer cells dying.